Nanobiotechnology and Nanomedicine Companies

 

Showing results 31 - 40 of 138 of companies in USA:

 
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
The company develops its proprietary E-SPR (Enhanced Surface Plasmon Resonance) technology platform for the detection of molecular interactions.
The company develops revolutionary microliter and nanoliter scale technology platforms for life sciences and drug discovery research.
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
A leading provider of cutting-edge technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper has compiled numerous best-in-class solutions and is aggressively innovating new technologies to bridge the gaps that exist in bringing in vitro assays to in vivo results and ultimately into cures for human disease.
Carestream Molecular Imaging is a leading provider of Kodak branded in vivo and in vitro optical molecular imaging solutions for life science and molecular biology research.
The company develops new treatments for cancer based on a portfolio of delivery technologies including liposomes, polymers and nanotechnologies.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Celsense is a biotechnology company offering novel MRI contrast agents (fluorochemical nanoparticles) that allow scientists and clinicians to monitor the position and quantity of transplanted cells non-invasively in vivo.
The company develops nanoparticle-based gene therapies for eye disease.